BioNTech Management
Management criteria checks 4/4
BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.25 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.14% of the company’s shares, worth $3.65B. The average tenure of the management team and the board of directors is 5.3 years and 4 years respectively.
Key information
Ugur Sahin
Chief executive officer
€3.1m
Total compensation
| CEO salary percentage | 22.9% |
| CEO tenure | 16.3yrs |
| CEO ownership | 17.1% |
| Management average tenure | 5.3yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03BioNTech: A Tale Of 2 Companies
Sep 20European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot
Sep 12CDC advisors to vote on COVID Omicron vaccines on Sept. 1
Aug 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
Compensation vs Market: Ugur's total compensation ($USD3.27M) is below average for companies of similar size in the US market ($USD13.52M).
Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.
CEO
Ugur Sahin (58 yo)
16.3yrs
Tenure
€3,056,000
Compensation
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 16.3yrs | €3.06m | 17.14% € 3.7b | |
| Co-Founder | 6.3yrs | €814.00k | 0.38% € 80.8m | |
| CFO & Member of Management Board | 2.8yrs | €1.32m | 0.00067% € 142.9k | |
| MD, COO & Member of Management Board | 10.3yrs | €821.00k | 0.31% € 66.8m | |
| Chief Strategy Officer | 4.3yrs | €1.41m | 0.0061% € 1.3m | |
| Chief Business Officer | 12.3yrs | €133.00k | 0.34% € 72.1m | |
| Chief Legal Officer & Member of the Management Board | less than a year | €848.00k | no data | |
| Senior Vice President of Corporate Development & Strategy | less than a year | no data | no data | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | no data | no data | |
| Senior Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | no data | no data | |
| Senior Vice President of Global R&D Digital | no data | no data | no data |
5.3yrs
Average Tenure
56yo
Average Age
Experienced Management: BNTX's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Supervisory Board Member | 1.8yrs | €90.00k | 0.00017% € 36.3k | |
| Independent Deputy Chairman Supervisory Board | 6.3yrs | €114.00k | no data | |
| Independent Supervisory Board Member | 16.3yrs | €80.00k | no data | |
| Independent Supervisory Board Chairman | 16.3yrs | €226.00k | 0.14% € 29.4m | |
| Member of Supervisory Board | less than a year | €46.00k | no data | |
| Supervisory Board Member | 1.8yrs | €105.00k | 0.00010% € 21.3k |
4.0yrs
Average Tenure
57.5yo
Average Age
Experienced Board: BNTX's board of directors are considered experienced (4 years average tenure).